Do analysts recommend QCLS or FLNA?

Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 350.65%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, QCLS or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is QCLS or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Cassava Sciences N/A -53.90% -34.20%

Do analysts rate QCLS or BHST?

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 243.64%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate CNTX or QCLS?

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 915.93%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CNTX or QCLS?

Context Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is CNTX or QCLS more profitable?

Context Therapeutics' return on equity of -59.95% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts prefer INCR or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INCR or QCLS more profitable?

InterCure's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts prefer TIL or QCLS?

Instil Bio currently has a consensus price target of $66.00, suggesting a potential upside of 759.38%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Instil Bio is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TIL or QCLS?

Instil Bio is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is TIL or QCLS more profitable?

Instil Bio's return on equity of -39.76% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Mymd Pharmaceuticals N/A -76.40% -35.10%

Mymd Pharmaceuticals (QCLS) Competitors

$3.42 -0.03 (-0.72%)

As of 01:12 PM Eastern

Compare

QCLS vs. FLNA, BHST, CNTX, INCR, and TIL

Should you buy Mymd Pharmaceuticals stock or one of its competitors? MarketBeat compares Mymd Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mymd Pharmaceuticals include Cassava Sciences (FLNA), BioHarvest Sciences (BHST), Context Therapeutics (CNTX), InterCure (INCR), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

How does Mymd Pharmaceuticals compare to Cassava Sciences?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Mymd Pharmaceuticals has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market.

Cassava Sciences' return on equity of -53.90% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Cassava Sciences	N/A	-53.90%	-34.20%

Cassava Sciences is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Mymd Pharmaceuticals and Mymd Pharmaceuticals both had 1 articles in the media. Mymd Pharmaceuticals' average media sentiment score of 1.87 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Mymd Pharmaceuticals	Very Positive
Cassava Sciences	Very Positive

Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 350.65%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cassava Sciences beats Mymd Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to BioHarvest Sciences?

Mymd Pharmaceuticals (NASDAQ:QCLS) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Mymd Pharmaceuticals has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 243.64%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mymd Pharmaceuticals has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioHarvest Sciences had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for BioHarvest Sciences and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat BioHarvest Sciences' score of 0.93 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Very Positive
BioHarvest Sciences	Positive

BioHarvest Sciences has higher revenue and earnings than Mymd Pharmaceuticals. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
BioHarvest Sciences	$34.51M	1.65	-$11.14M	-$0.59	N/A

Summary

BioHarvest Sciences beats Mymd Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Context Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Context Therapeutics' return on equity of -59.95% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Context Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 915.93%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Context Therapeutics had 5 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 6 mentions for Context Therapeutics and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat Context Therapeutics' score of 0.70 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Context Therapeutics	Positive
Mymd Pharmaceuticals	Very Positive

Summary

Context Therapeutics beats Mymd Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to InterCure?

InterCure (NASDAQ:INCR) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, InterCure had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for InterCure and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat InterCure's score of 1.45 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Positive
Mymd Pharmaceuticals	Very Positive

InterCure has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.3% of InterCure shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InterCure has higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.68	-$10.37M	$0.03	32.30
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

InterCure's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Summary

InterCure beats Mymd Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.87 equaled Mymd Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Instil Bio	Very Positive
Mymd Pharmaceuticals	Very Positive

Instil Bio's return on equity of -39.76% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Instil Bio has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Instil Bio currently has a consensus price target of $66.00, suggesting a potential upside of 759.38%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Instil Bio is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Instil Bio is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

Summary

Instil Bio beats Mymd Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$14.30M	$372.27M	$4.37B	$12.59B
Dividend Yield	N/A	N/A	30.61%	8.43%
P/E Ratio	-0.17	N/A	23.72	24.33
Price / Sales	N/A	94.28	142.20	92.04
Price / Cash	N/A	224.02	165.47	59.39
Price / Book	0.66	22.00	12.25	6.30
Net Income	-$11.63M	-$18.48M	$120.20M	$331.45M
7 Day Performance	-6.23%	-8.86%	-1.05%	-0.08%
1 Month Performance	-15.68%	-21.98%	-3.10%	-0.96%
1 Year Performance	N/A	-56.63%	11.05%	19.89%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	0.6068 of 5 stars	$3.43 -0.5%	N/A	N/A	$14.30M	N/A	N/A	6
FLNA Cassava Sciences	2.1852 of 5 stars	$1.19 +0.8%	$5.00 +320.2%	-49.5%	$57M	N/A	N/A	20	Positive News
BHST BioHarvest Sciences	2.5937 of 5 stars	$2.76 -3.5%	$10.00 +262.3%	-60.4%	$56.10M	$35.16M	N/A	N/A	News Coverage Gap Up High Trading Volume
CNTX Context Therapeutics	3.0981 of 5 stars	$0.59 -0.2%	$6.17 +937.3%	-14.9%	$54.72M	N/A	N/A	7	Analyst Upgrade Short Interest Increase High Trading Volume
INCR InterCure	1.3544 of 5 stars	$0.98 +1.0%	N/A	-36.1%	$53.04M	$270.20M	32.67	350	Positive News Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. FLNA, BHST, CNTX, INCR, and TIL

How does Mymd Pharmaceuticals compare to Cassava Sciences?

Summary

How does Mymd Pharmaceuticals compare to BioHarvest Sciences?

Summary

How does Mymd Pharmaceuticals compare to Context Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to InterCure?

Summary

How does Mymd Pharmaceuticals compare to Instil Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. FLNA, BHST, CNTX, INCR, and TIL

How does Mymd Pharmaceuticals compare to Cassava Sciences?

Which has more risk and volatility, QCLS or FLNA?

Is QCLS or FLNA more profitable?

Which has higher earnings and valuation, QCLS or FLNA?

Do insiders & institutionals have more ownership in QCLS or FLNA?

Does the media favor QCLS or FLNA?

Do analysts recommend QCLS or FLNA?

Summary

How does Mymd Pharmaceuticals compare to BioHarvest Sciences?

Which has more risk and volatility, QCLS or BHST?

Do analysts rate QCLS or BHST?

Is QCLS or BHST more profitable?

Do insiders and institutionals have more ownership in QCLS or BHST?

Does the media favor QCLS or BHST?

Which has higher valuation & earnings, QCLS or BHST?

Summary

How does Mymd Pharmaceuticals compare to Context Therapeutics?

Which has more risk & volatility, CNTX or QCLS?

Is CNTX or QCLS more profitable?

Which has better valuation and earnings, CNTX or QCLS?

Do institutionals & insiders hold more shares of CNTX or QCLS?

Do analysts rate CNTX or QCLS?

Does the media favor CNTX or QCLS?

Summary

How does Mymd Pharmaceuticals compare to InterCure?

Does the media prefer INCR or QCLS?

Which has more risk & volatility, INCR or QCLS?

Do analysts prefer INCR or QCLS?

Do institutionals and insiders have more ownership in INCR or QCLS?

Which has higher valuation and earnings, INCR or QCLS?

Is INCR or QCLS more profitable?

Summary

How does Mymd Pharmaceuticals compare to Instil Bio?

Does the media prefer TIL or QCLS?

Is TIL or QCLS more profitable?

Which has more volatility & risk, TIL or QCLS?

Do analysts prefer TIL or QCLS?

Do insiders and institutionals have more ownership in TIL or QCLS?

Which has better earnings and valuation, TIL or QCLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools